No association between the CYP1B1 C4326G polymorphism and endometrial cancer risk: A meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 9, 2011, Pages 2343-2348

  Wang, Xi Wen ^a   Chen, Yu Li ^a   Luo, Ya Li ^a   Liu, Qing Yi ^a  

^a Birth Defects Prevention Research and Transformation Team   (China)

Author keywords

CYP1B1; Endometrial cancer; Meta analysis; Polymorphism

Indexed keywords

CYTOCHROME P450, FAMILY 1, SUBFAMILY B, POLYPEPTIDE 1; UNSPECIFIC MONOOXYGENASE;

ALLELE; ARTICLE; CASE CONTROL STUDY; CONFIDENCE INTERVAL; ENDOMETRIUM TUMOR; ENZYMOLOGY; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; META ANALYSIS; RISK;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; ENDOMETRIAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; ODDS RATIO; POLYMORPHISM, GENETIC; RISK;

EID: 84866269394     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Aklillu E, Oscarson M, Hidestrand M, et al (2002). Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. Mol Pharmacol, 61, 586-94.
2. Ashton KA, Proietto A, Otton G, et al (2010). Polymorphisms in genes of the steroid hormone biosynthesis and metabolism pathways and endometrial cancer risk. Cancer Epidemiol, 34, 328-37.
3. Bailey LR, Roodi N, Dupont WD, et al (1998). Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res, 58, 5038-41.
4. Bejjani BA, Lewis RA, Tomey KF, et al (1998). Mutations in CYP1B1, the gene for cytochrome P4501B1, are the predominant cause of primary congenital glaucoma in Saudi Arabia Am J Hum Genet, 62, 325-33.
5. Cochran WG (1954). The combination of estimates from different experiments. Biometrics, 10, 101-29.
6. DerSimonian R, Laird N (1986). Meta-analysis in clinical tria ls. Control Clin Trials, 7, 177-88.
7. Doherty JA, Weiss NS, Freeman RJ, et al (2005). Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev, 14, 357-66.
8. Han X, Liehr JG (1994). DNA single-strand breaks in kidneys of Syrian hamsters treated with steroidal estrogens: hormone-induced free radical damage preceding renal malignancy. Carcinogenesis, 15, 997-1000.
9. Hanna IH, Dawling S, Roodi N, et al (2000). Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res, 60, 3440-4.
10. Hayashi SI, Watanabe J, Nakachi K, et al (1991). Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450 1A1 gene. J Biochem, 110, 407-11.
11. Hayes CL, Spink DC, Spink BC, et al (1996). 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci USA, 93, 9776-81.
12. Herrington CS (2001). What we could do now: molecular pathology of gynaecological cancer. Mol Pathol.54.222-4.
13. Higgins JP. Thompson SE (2002). Quantifying heterogeneity in a metaanalysis. Stat Med, 21, 1539-58.
14. Hirata H, Hinoda Y, Okayama N, et al (2008). CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility. Cancer, 112, 1964-73.
15. Key TJ, Pike MC (1988). The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer, 57, 205-12.
16. Li JJ, Hou X, Bentel J, et al (1998). Prevention of estrogen carcinogenesis in the hamster kidney by ethinylestradiol: some unique properties of a synthetic estrogen. Carcinogenesis, 19, 471-7.
17. Liehr JG (1990). Genotoxic effects of estrogens. Mutat Res, 238, 269-76.
18. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
19. McGrath M, Hankinson SE, Arbeitman L, et al (2004). Cytochrome P450 1B1 and catechol-O-methyltransferase polymorphisms and endometrial cancer susceptibility. Carcinogenesis, 25, 559-65.
20. Meyer UA, Gut J, Kronbach T, et al (1986). The molecular mechanisms of two common polymorphisms of drug oxidation-evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica, 16, 449-64.
21. Newbold RR, Liehr JG (2000). Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. Cancer Res, 60, 235-7.
22. Rylander-Rudqvist T, Wedrén S, Jonasdottir G, et al (2004). Cytochrome P450 1B1 gene polymorphisms and postmenopausal endometrial cancer risk. Cancer Epidemiol Biomarkers Prev, 13, 1515-20.
23. Salanti G, Sanderson S, Higgins JP (2005). Obstacles and opportunities in meta-analysis of genetic association studies. Genet Med, 7, 13-20.
24. Sasaki M, Kotcherguina L, Dharia A (2001). Cytosine-phosphoguanine methylation of estrogen receptors in endometrial cancer. Cancer Res, 61, 3262-6.
25. Sasaki M, Tanaka Y, Kaneuchi M, et al (2003). CYP1B1 gene polymorphisms have higher risk for endometrial cancer, and positive correlations with estrogen receptor alpha and estrogen receptor beta expressions. Cancer Res, 63, 3913-8.
26. Shimada T, Watanabe J, Kawajiri K, et al (1999). Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis, 20, 1607-13.
27. Sliwinski T, Sitarek P, Stetkiewicz T, et al (2010). Polymorphism of the ERalpha and CYP1B1 genes in endometrial cancer in a Polish subpopulation. J Obstet Gynaecol Res, 36, 311-7.
28. Stoilov I, Akarsu AN, Alozie I (1998). Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from polymorphisms disrupting either the hinge region or the conserved core structures of cytochrome P450 1B1. Am J Hum Genet, 62, 573-84.
29. Tao MH, Cai QY, Xu WH, et al (2006). Cytochrome P450 1B1 and catechol-O-methyltransferase genetic polymorphisms and endometrial cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev, 15, 2570-3.
30. Wang F, Zou YF, Sun GP, Su H, Huang F (2011). Association of CYP1B1 gene polymorphisms with susceptibility to endometrial cancer: a meta-analysis. Eur J Cancer Prev, 20, 112-20.
31. Wen W, Cai Q, Shu XO (2005). Cytochrome P450 1B1 and catechol-O-methyltransferase genetic polymorphisms and breast cancer risk in Chinese women: results from the shanghai breast cancer study and a meta-analysis. Cancer Epidemiol Biomarkers Prev.14.329-35.
32. Zhang D, Chen C, Fu X, et al (2008). A meta-analysis of DNA repair gene XPC polymorphisms and cancer risk. J Hum Genet, 53, 18-33.
33. Zhu BT, Conney AH (1998). Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis, 19, 1-27.
34. Zintzaras E, Chatzoulis DZ, Karabatsas CH, et al (2005). The relationship between C677T methylenetetrahydrofolate reductase gene polymorphism and retinopathy in type 2 diabetes: a metaanalysis. J Hum Genet, 50, 267-75.